Praxis Bioresearch Obtains FDA Clearance On the IND Application for Its Lead Candidate PRX-P4-003 In Alzheimer’s Disease Apathy
29 oct. 2024 07h48 HE
|
Praxis Bioresearch, Inc.
LOS ANGELES, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Praxis Bioresearch reports that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for...
Praxis Bioresearch Expands its Board of Directors with Appointment of Adam Levy
19 sept. 2023 16h00 HE
|
Praxis Bioresearch, Inc.
LOS ANGELES, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Praxis Bioresearch (“Praxis”), a biopharmaceutical company focused on the discovery and development of therapeutics for chronic neuropsychiatric and...
Praxis Bioresearch Presents Phase 0 Clinical Data for PRX-P4-003 at 14th Annual CTAD conference
09 nov. 2021 07h00 HE
|
Praxis Bioresearch, LLC
LOS ANGELES, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Praxis Bioresearch reports Clinical Phase 0 study data (PBR001) to demonstrate the desired pharmacokinetic profile for its lead product candidate,...
Praxis Bioresearch Awarded $2.9 Million Fast-Track SBIR Grant for Development of Novel Therapy for Apathy in Alzheimer’s Disease
05 août 2021 04h00 HE
|
Praxis Bioresearch, LLC
LOS ANGELES, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Praxis is proud to announce to be the recipient of a Fast-Track SBIR award to develop treatment for apathy in Alzheimer’s Disease. The award, in its...
Praxis Bioresearch Announces Positive Results from Clinical Microdose Study in Humans Showing Oral Activation of Its Novel Prodrug Stimulant PRX-P4-003
23 juin 2021 06h07 HE
|
Praxis Bioresearch, LLC
All subjects who were dosed with Prodrug PRX-P4-003 had systemic exposure of the active moiety (-)-fencamfamine suggesting robust intestinal conversionAs anticipated, fed subjects showed earlier...
Praxis Bioresearch Announces Issuance of U.S. Patent on its Prodrug Stimulant PRX-P4-003
23 juin 2020 08h30 HE
|
Praxis Bioresearch, LLC
SACRAMENTO, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Praxis Bioresearch, a biopharmaceutical company focused on the discovery and development of novel therapeutics for chronic central nervous...